- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01712581
Heart Map Study -Determination of Myocardial Relaxation Times Values in Healthy Volunters (HeartMS)
Determination of Myocardial Relaxation Times Values in Healthy Volunters
T1, T2 and T2* relaxation times, as determined with cardiac MRI, are markers of myocardial tissue content (water, fibrosis, iron).
The aim of study is to determine the normal values of T1, T2 and T2* relaxation times in healthy volunters aged 18-69 years using 1.5T clinical MRI.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cardiac MRI is more and more used in patients with ischaemic and non-ischaemic heart diseases. One major strength of MRI is its great potential for tissue characterization.
For early detection and follow-up of patients with hemosiderosis, who are at high risk of myocardial iron overload, cardiac MRI seems to be the most reliable, more reproducible and less invasive method. In addition MRI does not require injection of contrast media. It is commonly accepted that myocardial T2 * value of less than 20 ms corresponds to iron overload in the myocardium. However, this value is based on a small sample study and nomogram based on age were not published. The determination of normal values in a population of healthy controls according to age appears to be a prerequisite for reliable interpretation of imaging data.
Moreover, myocardial edema and fibrosis are more and more evaluated with cardiac MRI using T1 and T2 myocardial relaxation times. As for T2* values, normogram of T1 and T2 values based on age were not published.
The increasing use of T1, T2 and T2* mapping sequences in clinical practice for tissue characterization of the myocardium justify the implementation of a study in healthy volunteers to determine normograms based on age.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rouen, France, 76031
- Rouen University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Volunteers over the age of 18 and less than 70
- Volunteers able to understand and sign the consent and to give written informed consent
- Female contraceptives if of childbearing age
- Registered or entitled to social security system
- Volunteers able to maintain supine for 20 minutes
Exclusion Criteria:
- Major protected/under guardianship
- Volunteers unable to maintain the supine position for 20 minutes
- Claustrophobia
- Volunteers with history of PRBC transfusion
- Volunteers with history of hematologic disease or a disruption of iron status
- Volunteers with history of cardiac disease including arrhythmias
- Hypertension
- Diabetes
- Contra-indication for MRI: metal fragments in the eyes; implantable cardiac, neurological or ENT device; osteosynhesis material not compatible with MRI
- Women who are pregnant or likely to be
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Healthy volunters
175 Healthy volunters in the cohorte divided in 7 groups of age: 18-19 years old (ratio M/F: 1/1) 20-24 years old (ratio M/F: 1/1) 25-29 years old (ratio M/F: 1/1) 30-39 years old (ratio M/F: 1/1) 40-49 years old (ratio M/F: 1/1) 50-59 years old (ratio M/F: 1/1) 60-69 years old (ratio M/F: 1/1)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The main objective is to determine normal T2 * values of the myocardium in a large adult population of healthy volunteers, using 1.5T cardiac MRI.
Time Frame: 24h
|
24h
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The secondary objectives are to determine normal T1 and T2 values of the myocardium in a large adult population of healthy volunteers, using 1.5T cardiac MRI.
Time Frame: 24h
|
24h
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012/071/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Normal Myocardial T1, T2 and T2* Values
-
Boston Scientific CorporationCompleted
-
Centre Hospitalier Universitaire Dinant Godinne...RecruitingSupraglottic Squamous Cell Carcinoma | Early Stage (T1-T2, N0-N1,M0)Belgium
-
University Hospital, MontpellierRecruitingCancer T1-N0 or T2-N0 of the Oral CavityFrance
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Seoul National University... and other collaboratorsTerminatedSurgery | Tongue Cancer | Squamous Cell Carcinoma | Resection Margin | Tongue Cancer TNM Staging Primary Tumor (T) T1 | Tongue Cancer TNM Staging Primary Tumor (T) T2Korea, Republic of
-
University of PadovaIstituto Oncologico Veneto IRCCS; Azienda Ulss 2 Marca Trevigiana; Associazione... and other collaboratorsRecruitingRectal Cancer Stage T1-T2 | Rectal Cancer Nodal MetastasisItaly
-
XIANG YANQUNRecruitingNasopharyngeal Carcinoma | T2-3N0 or T1-2N1 | EBV-DNA≤4000 Copy/mlChina
-
Texas Woman's UniversityRecruitingSpinal Cord Injury at T2 and BelowUnited States
-
AstraZenecaUppsala Clinical Research, Uppsala, SwedenCompletedT2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)Sweden
-
Chinese University of Hong KongNot yet recruitingDiabete Mellitus | T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)Hong Kong
-
Yantai Yuhuangding HospitalSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Not yet recruitingNeoadjuvant Therapy | Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast CancerChina
Clinical Trials on Magnetic Resonance Imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedThoracic Spine NeoplasmUnited States
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Institute of Neurological Disorders...RecruitingGlioma | Glioblastoma | Metastatic Malignant Neoplasm in the BrainUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell CarcinomaUnited States, Canada, Korea, Republic of, Saudi Arabia, Mexico, Chile, Colombia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...United States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnColorectal Carcinoma Metastatic in the LiverUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted